| "One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center. | |
| | |
MedLine Citation:
|
PMID: 23299464 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
To evaluate in a single center retrospectively the efficacy and tolerability of a weekly regimen, which alternates temozolomide (TMZ) in patients with recurrent or progressive high-grade glioma (HGG). From January 2005 until June 2011, 54 patients with recurrent or progressive HGG were treated with TMZ 150 mg/m²/day on days 1-7 and 15-21 of a 28-day cycle ("one week on-one week off" scheme; TMZ 7/14) with individual dose adjustment depending on toxicity. The majority of patients (n = 48, 89 %) was treated at first tumor recurrence or progression. All patients had received prior radiotherapy with or without concomitantly administered TMZ and, optionally, adjuvant chemotherapy. After initiation of TMZ 7/14, MRI was obtained every 8-12 weeks. Tumor response or progression was assessed according to Macdonald criteria. Blood examinations were performed weekly. Toxicity was evaluated according to Common Terminology Criteria for Adverse Events (CTCAE; version 3.0). A total of 434 treatment weeks with TMZ 7/14 were delivered. The median number of treatment weeks was 7 (range, 1-41 weeks). No grade 4 hematological toxicity and no opportunistic infections occurred. Patients with neutropenia were not observed. Two patients developed grade 3 and 4 patients grade 2 leukocytopenia. Thrombocytopenia grade 3 and grade 2 occurred in 4 patients and 6 patients, respectively. The progression-free survival (PFS) rate at 6 months was 43 %. Median PFS from treatment initiation was 18 weeks (95 % CI, 14-22 weeks) and median overall survival (OS) was 37 weeks (95 % CI, 31-42 weeks). The rates for PFS and OS at 1 year were 24 and 28 %, respectively. Our data suggest that treatment with TMZ 7/14 is safe and effective in patients with recurrent or progressive HGG. |
| | |
Authors:
|
Norbert Galldiks; Theresa Berhorn; Tobias Blau; Veronika Dunkl; Gereon R Fink; Michael Schroeter |
Related Documents
:
|
23429354 - The spectrum of type i cryoglobulinemia vasculitis: new insights based on 64 cases. 23280694 - Disseminated tumor cells and their prognostic significance in non-metastatic prostate c... 7967514 - A sensitive multilayer immunoalkaline phosphatase method for detection of p-glycoprotei... 23762994 - Experience with high-intensity focused ultrasound therapy for management of organ-confi... 8799414 - Adjuvant therapy following pancreatic resection for pancreatic duct carcinoma: a prospe... 19384934 - Shoulder morbidity after pectoralis major flap reconstruction for head and neck cancer. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2013-1-9 |
Journal Detail:
|
Title: Journal of neuro-oncology Volume: - ISSN: 1573-7373 ISO Abbreviation: J. Neurooncol. Publication Date: 2013 Jan |
Date Detail:
|
Created Date: 2013-1-9 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8309335 Medline TA: J Neurooncol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Department of Neurology, University of Cologne, Kerpener Str. 62, 50924, Cologne, Germany, norbert.galldiks@uk-koeln.de. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Tryptophan PET in pretreatment delineation of newly-diagnosed gliomas: MRI and histopathologic corre...
Next Document: Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal...